Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of the Express Plus Range
Sponsor: Vitaflo International, Ltd
Summary
A prospective, open label, acceptability study to evaluate PKU, MSUD, HCU, TYR and GA express plus in the dietary management of 40 patients with IEM. The following parameters will be assessed: adherence to prescribed dietary intakes, palatability, usability, gastrointestinal tolerance, clinically relevant routine biochemical parameters, timeframe to transition and contribution of the express plus range to overall protein substitute intake over a 28 day period.
Official title: A Study To Evaluate The Acceptability Of the Express Plus Range, Foods For Special Medical Purposes (FSMP), In Children And Adults With Inborn Errors of Metabolism (IEM)
Key Details
Gender
All
Age Range
3 Years - Any
Study Type
INTERVENTIONAL
Enrollment
28
Start Date
2021-06-14
Completion Date
2026-01-21
Last Updated
2026-05-18
Healthy Volunteers
No
Conditions
Interventions
PKU express plus
PKU express plus is a powdered protein substitute for the dietary management of PKU. It is formulated in a variety of flavours to provide a convenient, low volume, lower calorie, pre-measured protein substitute, containing a full micronutrient profile.
Locations (6)
Royal Belfast Hospital for Sick Children
Belfast, United Kingdom
Birmingham Women's and Children's Hospital
Birmingham, United Kingdom
Bristol Royal Hospital for Children
Bristol, United Kingdom
Greater Glasgow and Clyde NHS Foundation Trust
Glasgow, United Kingdom
Great Ormond Street Hospital for Children
London, United Kingdom
Nottingham Children's Hospital
Nottingham, United Kingdom